BUZZ - Vaxcyte shares dip slightly after raising 1 billion dollars for pneumococcal vaccine development
路透社2026/10/07 11:14On October 7: Vaxcyte (PCVX.O) shares fell 0.3% in premarket trading on Wednesday to $66.50, after the company completed a $1.1 billion financing round. On Tuesday night, PCVX announced the pricing (link) of approximately 7.8 million shares of common stock and pre-funded warrants at $64 per share, raising $500 million in total; simultaneously, the company launched a public offering of $500 million of convertible senior notes with a coupon rate of 1.5%, maturing on October 15, 2032. The conversion price of the convertible notes is $89.60, representing a 40% premium over the equity offering price. On Monday, PCVX shares surged around 31% after the company announced that its pneumococcal vaccine VAX-31 met all primary endpoints in late-stage clinical trials (link), generating an immune response at least comparable to that of Pfizer’s Prevnar 20 (PFE.N) and Merck’s Capvaxive (MRK.N). On Tuesday, following the launch of the public offering (link), the stock closed down nearly 10% at $66.70. PCVX plans to use the net proceeds from this offering to fund clinical development of the VAX-31 adult and pediatric programs, including the ongoing adult Phase III clinical trial of VAX-31. Jefferies, Leerink, BofA, Evercore, Goldman Sachs, and Guggenheim are joint book-running managers for the equity offering; Jefferies, Leerink, BofA, Goldman Sachs, and Evercore act as lead managers for the convertible notes transaction. As of Tuesday’s close, PCVX shares are up about 45% year-to-date.
October 7 - ** Vaxcyte (PCVX.O) shares fell 0.3% to $66.50 in pre-market trading on Wednesday after the company completed a $1 billion financing
** PCVX announced Tuesday evening (link) that it priced approximately 7.8 million shares of common stock and pre-funded warrants at $64 per share, raising a total of $500 million; at the same time, it launched a public offering of $500 million in convertible bonds with a coupon rate of 1.5%, which will mature on October 15, 2032
** The conversion price of the convertible bonds is $89.60, representing a 40% premium to this stock offering price
** On Monday, PCVX shares surged about 31% after the company announced that its pneumococcal vaccine VAX-31 met all primary endpoints in late-stage clinical trials (link), and produced immune responses at least comparable to Pfizer's PFE.N Prevnar 20 and Merck's MRK.N Capvaxive
** On Tuesday, after the company launched (link) the public offerings, the stock closed down nearly 10% at $66.70
** The company plans to use the net proceeds from this offering to fund clinical development of the VAX-31 adult and pediatric programs, including the ongoing VAX-31 adult Phase III clinical trial
** Jefferies, Leerink, BofA Securities, Evercore, Goldman Sachs, and Guggenheim acted as joint book-running managers for the equity offering; Jefferies, Leerink, BofA Securities, Goldman Sachs, and Evercore served as lead underwriters for the convertible bonds
** As of Tuesday's close, PCVX shares were up approximately 45% year-to-date
(To assist non-English speakers, Reuters provides its reports automatically translated into several other languages. Automated translation may contain errors or lack necessary context, and Reuters does not guarantee the accuracy of the automated text. It is provided for convenience only. Reuters does not accept any responsibility for damage or losses resulting from the use of this automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Swiss Franc: Range trading persists against US Dollar – UOB
Exclusive Report – According to two sources, the first liquefied natural gas production line of Qatar Energy’s NFE project is ready and about to start operation.
According to two sources familiar with the matter, the first liquefied natural gas (LNG) production line under the "North Field East" expansion project by QatarEnergy is now ready and about to start operation, with the first batch of natural gas expected to be produced in November. This could provide Qatar with a way to restore some of the output lost due to attacks from Iran.
BlackRock’s Remarkable AI Scenario: “Bitcoin (BTC) Takes the Lead!”
BUZZ - Citi upgrades XPO rating to "Buy" due to increased market share and strong pricing power
October 7 - Citigroup has upgraded logistics company XPO (XPO.N) from “Neutral” to “Buy,” and raised its target price to $224, indicating an upside potential of about 22% from the previous trading day’s closing price. The brokerage stated that the upgrade was made after the stock declined from the $230 range to its current level of $183 per share. It also added that the recent broad pullback in the transportation sector has created a "more favorable risk-reward setup" for the third-quarter earnings season. Citigroup noted, "Notably, XPO has been particularly optimistic about its Q3 earnings, expecting an opportunity to gain market share and maintain pricing power." Among 26 brokerages, 19 rate the stock "Buy" or above, 6 rate it "Hold," and 1 rates it "Sell"; the median target price is $238 according to data compiled by the London Stock Exchange Group (LSEG). As of yesterday’s close, the stock had risen 35% year-to-date.
